​

Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Halozyme Therapeutics Ownership Summary

Halozyme Therapeutics is owned by 105.19% institutional investors, 1.11% insiders. Blackrock is the largest institutional shareholder, holding 13.88% of HALO shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.56% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockHalozyme Therapeutics105.19%1.11%-6.30%
SectorHealthcare Stocks 245.30%12.08%-157.38%
IndustryBiotech Stocks 381.70%11.71%-293.40%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock17.62M13.88%$922.58M
Blackrock funding, inc. /de13.27M11.23%$1.04B
Vanguard group11.57M9.87%$778.45M
Vanguard capital management5.35M4.53%$418.85M
State street5.18M4.38%$405.38M
Invesco3.18M2.69%$248.74M
Morgan stanley2.83M2.40%$221.71M
Boston partners2.77M2.35%$216.82M
Bank of america corp /de/2.74M2.32%$214.50M
Geode capital management2.52M2.13%$197.28M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Koa wealth management92.99K6.65%$10.27M
Panoramic capital116.42K3.92%$9.11M
Cooper investors pty65.93K3.82%$7.28M
Cutter capital management, lp120.00K3.33%$7.66M
Snyder capital management l p2.40M3.24%$187.54M
Future fund142.01K3.19%$11.11M
2xideas87.77K2.96%$6.87M
Mizuho markets cayman lp834.50K2.45%$65.32M
South street advisors238.69K2.43%$18.68M
Bernzott capital advisors76.38K2.39%$5.98M

Top Buyers

HolderShares% AssetsChange
Norges bank1.48M0.01%1.48M
Sixth street partners management company1.32M0.01%1.32M
Los angeles capital management1.94M0.56%1.25M
Congress asset management co /ma2.28M1.63%1.05M
Wasatch advisors lp1.05M0.86%1.05M

Top Sellers

HolderShares% AssetsChange
Dld asset management, lp---30.00M
Macquarie group---1.55M
Jupiter asset management97.81K0.04%-1.51M
Mizuho markets americas393.08K0.48%-930.46K
Capital world investors---871.90K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.48M0.01%1.48M$116.13M
Sixth street partners management company1.32M0.01%1.32M$103.52M
Wasatch advisors lp1.05M0.86%1.05M$115.88M
Mizuho markets cayman lp834.50K2.45%834.50K$65.32M
Frontier capital management342.57K0.25%342.57K$26.81M

Sold Out

HolderChange
Curio wealth-1.00
Truvestments capital-1.00
Total investment management-1.00
Nemes rush group-2.00
Activest wealth management-3.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20266773.99%124,275,9253.18%1051.01%37312.35%203-5.58%
Mar 31, 20266310.64%116,597,570-5.33%970.88%3230.94%206-8.85%
Dec 31, 2025371-39.58%62,451,323-58.49%530.35%186-37.79%135-43.04%
Sep 30, 2025351-37.21%58,910,289-54.67%480.42%159-40.67%146-31.78%
Jun 30, 2025552-1.08%129,712,8686.64%1061.10%263-16.51%21229.27%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Mid-Cap ETF4.04M3.56%-1.44K
Vanguard MStar Total Stk Mkt Idx Invest3.77M3.32%-4.57K
Vanguard US Total Market Shares ETF4.03M3.27%3.36K
Vanguard Morn Total Stk Mkt Idx Investor3.76M3.17%-71.00
Vanguard Total Stock Mkt Idx Inv3.76M3.17%-71.00
iShares Russell 2000 ETF3.13M2.54%-
Vanguard Small Cap Index2.55M2.25%-174.18K
Aviva Investors GlConvtAbsRet I USD Acc2.74M2.16%2.74M
SPDR® S&P Biotech ETF2.18M1.86%4.86K
JHancock Disciplined Value Mid Cap I1.68M1.48%-24.58K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 08, 2026Torley Helen PRESIDENT AND CEOSell$336.53K
Oct 06, 2026Torley Helen PRESIDENT AND CEOSell$656.00K
Oct 06, 2026Torley Helen PRESIDENT AND CEOSell$248.17K
Oct 08, 2026Torley Helen PRESIDENT AND CEOSell$520.34K
Oct 07, 2026Torley Helen PRESIDENT AND CEOSell$954.87K

Insider Transactions Trends

DateBuySell
2027 Q1--
2026 Q1--
2025 Q4-13
2025 Q3-27
2025 Q2-7

HALO Ownership FAQ

Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 105.19%, followed by 1.11% insiders and -6.30% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 381.70%, which Halozyme Therapeutics falls below.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Blackrock (17.62M shares, 13.88%), Blackrock funding, inc. /de (13.27M shares, 11.23%), and Vanguard group (11.57M shares, 9.87%). Together, they hold 34.98% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Koa wealth management is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.65% of its assets in 92.99K Halozyme Therapeutics shares, valued at 10.27M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.56% of its total shares outstanding invested in 4.04M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools